ArticleLung2026
Social Vulnerability Index is Associated with Increased Risk of Malignancy in Screen-Detected High-Risk Pulmonary Nodules.
Article in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSmoking history and age are established lung cancer risk factors incorporated into screening guidelines. Social vulnerability index (SVI), a social determinant of health, has also been associated with cancer risk. We investigated the association between SVI and malignancy in high-risk, screen-detected pulmonary nodules.
methodsPatients with lung-RADS 4A, 4B, or 4X nodules identified on low-dose computed tomography screening at a single institution (2015-2024) were included. Non-Illinois residents, patients with incomplete address data, loss to follow-up, or declined evaluation were excluded. Malignancy was confirmed through clinical assessment, staging, and positron emission tomography imaging. SVI was determined by geocoding patient addresses to census tracts and applying the CDC tract-level SVI calculator. Logistic regression assessed associations between SVI and malignancy, including interaction models evaluating whether the association varied by dominant nodule size. Youden's analysis identified the optimal SVI cutpoint.
resultsAmong 398 patients, 50% were male and 56% White. Median age was 67 years (IQR 63-72), smoking history 40 pack-years (IQR 30-50), nodule size 1.1 cm (IQR 0.8-1.5), and SVI 0.62 (IQR 0.31-0.83). Malignancy was diagnosed in 36% (144/398). Receiver operating characteristic analysis identified an optimal SVI cutpoint of 0.50 with 68% sensitivity for malignancy. On multivariable analysis, SVI ≥ 0.50 was associated with increased odds of malignancy (OR 1.56, 95% CI 1.01-2.42, p = 0.046). Significant interactions between SVI and nodule size were observed for continuous SVI (OR 4.08, 95% CI 1.49-11.18, p = 0.006) and binary SVI ≥ 0.50 (OR 1.93, 955 CI 1.10-3.39, p = 0.022).
conclusionHigher SVI was associated with malignant pulmonary nodules, particularly in smaller or indeterminate nodules.
Indexed as
Identifiers
42365202What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.